$93.42
-0.47[-0.50%]
Last update: 11:32AM Get Real Time Here
Colgate-Palmolive
(NYSE:CL)Colgate-Palmolive Stock (NYSE:CL), Analyst Ratings, Price Targets, Predictions
Colgate-Palmolive Co has a consensus price target of $83.41, established from looking at the 78 latest analyst ratings. The last 3 analyst ratings were released from Morgan Stanley, Argus Research, and Barclays on May 28, 2024, May 15, 2024, and April 30, 2024. With an average price target of $98.33 between Morgan Stanley, Argus Research, and Barclays, there's an implied 5.26% upside for Colgate-Palmolive Co from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Morgan Stanley
Argus Research
Barclays
Wells Fargo
Stifel
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Colgate-Palmolive
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/28/2024 | Buy Now | 10.25% | Morgan Stanley | Dara Mohsenian | $101 → $103 | Maintains | Overweight | Get Alert |
| 05/15/2024 | Buy Now | 14.54% | Argus Research | Chris Graja | $97 → $107 | Maintains | Buy | Get Alert |
| 04/30/2024 | Buy Now | -9.01% | Barclays | Lauren Lieberman | $84 → $85 | Maintains | Equal-Weight | Get Alert |
| 04/29/2024 | Buy Now | -1.52% | Wells Fargo | Chris Carey | $90 → $92 | Maintains | Equal-Weight | Get Alert |
| 04/29/2024 | Buy Now | 1.69% | Stifel | Mark Astrachan | $94 → $95 | Maintains | Buy | Get Alert |
| 04/29/2024 | Buy Now | 7.04% | B of A Securities | Bryan Spillane | $90 → $100 | Maintains | Buy | Get Alert |
| 04/29/2024 | Buy Now | 1.69% | RBC Capital | Nik Modi | $88 → $95 | Maintains | Sector Perform | Get Alert |
| 04/16/2024 | Buy Now | 7.04% | Citigroup | Filippo Falorni | $95 → $100 | Maintains | Buy | Get Alert |
| 04/12/2024 | Buy Now | -10.08% | Barclays | Lauren Lieberman | $82 → $84 | Maintains | Equal-Weight | Get Alert |
| 04/10/2024 | Buy Now | 0.62% | Stifel | Mark Astrachan | $89 → $94 | Maintains | Buy | Get Alert |
| 04/08/2024 | Buy Now | 2.76% | Evercore ISI Group | Robert Ottenstein | $90 → $96 | Maintains | Outperform | Get Alert |
| 03/01/2024 | Buy Now | -0.45% | Goldman Sachs | Jason English | → $93 | Reinstates | → Buy | Get Alert |
| 01/29/2024 | Buy Now | -0.45% | Morgan Stanley | Dara Mohsenian | $85 → $93 | Maintains | Overweight | Get Alert |
| 01/29/2024 | Buy Now | 1.69% | UBS | Peter Grom | $93 → $95 | Maintains | Buy | Get Alert |
| 01/29/2024 | Buy Now | -5.8% | Wells Fargo | Chris Carey | $80 → $88 | Maintains | Equal-Weight | Get Alert |
| 01/29/2024 | Buy Now | -2.59% | Raymond James | Olivia Tong | → $91 | Upgrade | Market Perform → Outperform | Get Alert |
| 01/18/2024 | Buy Now | -3.66% | JP Morgan | Andrea Teixeira | $88 → $90 | Maintains | Overweight | Get Alert |
| 01/16/2024 | Buy Now | -12.22% | Barclays | Lauren Lieberman | $75 → $82 | Maintains | Equal-Weight | Get Alert |
| 12/15/2023 | Buy Now | -3.66% | B of A Securities | Bryan Spillane | → $90 | Upgrade | Neutral → Buy | Get Alert |
| 11/29/2023 | Buy Now | -5.8% | JP Morgan | Andrea Teixeira | $83 → $88 | Maintains | Overweight | Get Alert |
| 11/13/2023 | Buy Now | -6.87% | Jefferies | Kaumil Gajrawala | → $87 | Initiates | → Buy | Get Alert |
| 10/30/2023 | Buy Now | -14.37% | RBC Capital | Nik Modi | $79 → $80 | Maintains | Sector Perform | Get Alert |
| 10/30/2023 | Buy Now | -9.01% | Morgan Stanley | Dara Mohsenian | $89 → $85 | Maintains | Overweight | Get Alert |
| 10/17/2023 | Buy Now | -19.72% | B of A Securities | Bryan Spillane | $85 → $75 | Maintains | Neutral | Get Alert |
| 10/16/2023 | Buy Now | -13.29% | Stifel | Mark Astrachan | $85 → $81 | Upgrade | Hold → Buy | Get Alert |
| 10/12/2023 | Buy Now | -21.86% | Barclays | Lauren Lieberman | $81 → $73 | Maintains | Equal-Weight | Get Alert |
| 10/12/2023 | Buy Now | -13.29% | JP Morgan | Andrea Teixeira | $85 → $81 | Maintains | Overweight | Get Alert |
| 10/11/2023 | Buy Now | -9.01% | Citigroup | Filippo Falorni | $92 → $85 | Maintains | Buy | Get Alert |
| 09/22/2023 | Buy Now | -10.08% | HSBC | Alejandro Zamacona | → $84 | Initiates | → Buy | Get Alert |
| 08/01/2023 | Buy Now | -13.29% | Barclays | Lauren Lieberman | $77 → $81 | Maintains | Equal-Weight | Get Alert |
FAQ
What is the target price for Colgate-Palmolive (CL)?
The latest price target for Colgate-Palmolive (NYSE: CL) was reported by Morgan Stanley on May 28, 2024. The analyst firm set a price target for $103.00 expecting CL to rise to within 12 months (a possible 10.25% upside). 32 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Colgate-Palmolive (CL)?
The latest analyst rating for Colgate-Palmolive (NYSE: CL) was provided by Morgan Stanley, and Colgate-Palmolive maintained their overweight rating.
When was the last upgrade for Colgate-Palmolive (CL)?
The last upgrade for Colgate-Palmolive Co happened on January 29, 2024 when Raymond James raised their price target to $91. Raymond James previously had a market perform for Colgate-Palmolive Co.
When was the last downgrade for Colgate-Palmolive (CL)?
The last downgrade for Colgate-Palmolive Co happened on May 3, 2022 when Atlantic Equities changed their price target from $92 to $80 for Colgate-Palmolive Co.
When is the next analyst rating going to be posted or updated for Colgate-Palmolive (CL)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Colgate-Palmolive, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Colgate-Palmolive was filed on May 28, 2024 so you should expect the next rating to be made available sometime around May 28, 2025.
Is the Analyst Rating Colgate-Palmolive (CL) correct?
While ratings are subjective and will change, the latest Colgate-Palmolive (CL) rating was a maintained with a price target of $101.00 to $103.00. The current price Colgate-Palmolive (CL) is trading at is $93.42, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.